
We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our…

We are developing the future of drug discovery with a platform to discover, develop, and deliver drug candidates for challenging targets. Sign up for our quarterly newsletter to keep up with our…
Founded / Launch: February 29, 2024
Headquarters: Copenhagen and Lausanne
Technology: AI-enabled nGen platform for orally dosable macrocycles
Total reported funding: €116M (seed + Series A)
Employee count (reported): 45
Drug discovery and development for oral macrocycle therapeutics; replacing injectable biologics.
2024
Biotechnology / Biopharmaceuticals
€26M
Company launch announcement accompanied seed financing
€90M
Series A brought total reported funding to €116M; other participants included Forbion, Novo Holdings, Lilly Ventures, Cormorant, and the Export and Investment Fund of Denmark
“Investors include venture funds and corporate VC (Novo Holdings, Forbion, NEA, Lilly Ventures) and institutional/co-investors (Cormorant, Export and Investment Fund of Denmark)”
| Company |
|---|
About Orbis Medicines
Orbis Medicines is a pioneering biotech company transforming drug discovery with cutting-edge chemistry and data-driven approaches to develop oral alternatives to injectable biologics. Orbis’ nGen platform designs macrocycles with oral bioavailability by combining AI technologies with automated synthesis and high-throughput screening of real compounds.
Orbis Medicines have an established R&D site in Copenhagen that includes a state-of-the-art laboratory and a team of +20 experienced technical professionals and scientists.
Orbis Medicines has just been awarded a 2025 Endpoints 11 title as one of biopharma's most exciting start-ups.
This marks the first time a Nordic biotech has received this honor – highlighting the disruptive potential of Orbis Medicines. With a recent EUR 90 million Series A funding round, led by top-tier investors such as NEA, Eli Lilly, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion, Orbis Medicines are well-positioned for significant growth and long-term success. The confidence of these investors validates the potential to bring groundbreaking therapies to the market.
Orbis Medicines offer the excitement of a start-up, opportunities for professional growth, and the opportunity to be at the forefront of biotech innovation. Your ideas and contributions will shape the future of medicine. Please visit the website for more details; www.orbismedicines.com
About the role
We are seeking a highly skilled Senior Scientist for the Screening Biology department, to play a key role in the development, automation, and execution of advanced high-throughput screening strategies at Orbis Medicines.
In this role, you will develop robust and scalable biological assays by combining strong scientific knowledge with hands-on laboratory work. This position offers the opportunity to shape screening approaches at the core of Orbis’ discovery engine in close collaboration with the Platform Chemistry and AI & Computational Drug Design departments.
This is a hands-on senior role, where you will:
Your main tasks will include :
compound interactions
insights for project team
Scientific leadership & collaboration
Chemistry
and AI/Data Science) to ensure alignment across hit identification, hit validation, and progression of
hits to advanced hits
Your Skills and Expertise
You hold a PhD in a relevant field combined with several years of relevant industry experience, including strong hands-on experience with assay development and high throughput screening, including development of cellular screening assays. You have experience working with automation and liquid handling systems and preferably experience with DEL screening.
Experience with biophysical techniques such as SPR, DSF, ITC or similar methods is considered an advantage.
You enjoy working hands-on in the laboratory and are able to combine strong scientific depth with practical execution. You thrive in an innovative, fast-paced environment and are motivated by contributing directly to experimental work and data generation.
Application
Please apply via the link.
Orbis Medicines collaborates with DEDENROTH on this recruitment. Please contact Mia Danielsen to express your interest or if you have any questions about the role or the process.
Phone: +45 26178142 / Email: md@dedenroth-consulting.com
Your next opportunity is in here somewhere. Sign up to explore 52,000+ startups and their open roles. No spam. No gamification. Just jobs.
52,000+
Startups
65,000+
Open Roles
1,500+
New This Week